DOCSLIB.ORG

The Findings and Impact of Nonrehydrated Guaiac Examination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Findings and Impact of Nonrehydrated Guaiac Examination ORIGINAL INVESTIGATION The Findings and Impact of Nonrehydrated Guaiac Examination of the Rectum (FINGER) Study A Comparison of 2 Methods of Screening for Colorectal Cancer in Asymptomatic Average-Risk Patients Edmund J. Bini, MD; Roshini C. Rajapaksa, MD; Elizabeth H. Weinshel, MD Background: Testing stool for occult blood at the time ity fee for endoscopy, and the pathology fee for the of digital rectal examination (DRE) has been discour- biopsy specimens. aged because it is thought to increase the number of false- positive test results. Results: During the 5-year study period, 672 patients were evaluated and a colonic source of occult bleeding was iden- tified in 145 patients (21.6%). The predictive value of a posi- Objective: To compare the diagnostic yield of colonos- tive fecal occult blood test result (22.0% vs 21.3%, P = .85) copy and the cost per cancer detected in asymptomatic andthecostpercancerdetected($7604.80vs$7814.54)were patients with a positive fecal occult blood test result ob- no different in the DRE and SPS groups, with carcinomas tained by DRE with that obtained from spontaneously being detected in 11.7% and 11.3% of patients, respectively. passed stool (SPS) samples. Conclusions: Testing stool for occult blood at the time Methods: We reviewed the medical records of con- of DRE does not increase the number of false-positive test secutive asymptomatic patients at average risk for colo- results or the cost per cancer detected in asymptomatic rectal cancer who were referred for colonoscopy to patients at average risk for colorectal cancer. In this pa- evaluate a positive fecal occult blood test result tient population, all individuals should be evaluated by full obtained by DRE (n = 282) or SPS samples (n = 390). colonoscopy regardless of the method of stool collection. The cost of colonoscopy was estimated by adding the physician fee under Medicaid reimbursement, the facil- Arch Intern Med. 1999;159:2022-2026 CREENING FOR fecal occult In clinical practice, asymptomatic in- blood has been shown to re- dividuals with a positive FOBT result ob- duce mortality from colorec- tained by DRE are often referred for a colo- tal cancer,1-3 the second lead- noscopic evaluation.10 To date, there are ing cause of cancer death in almost no data on the diagnostic yield of Sthe United States.4 Because 70% to 80% of colonoscopy in asymptomatic patients with colorectal cancers are diagnosed in “av- a positive FOBT result obtained by DRE. The erage-risk” patients,5 the American Can- aims of this study were to compare the di- cer Society recommends annual fecal oc- agnostic yield of colonoscopy in patients cult blood testing (FOBT) of stool samples with a positive FOBT result obtained by DRE in all patients aged 50 years or older us- with that obtained by SPS sampling and to ing 3 specimens obtained from spontane- determine the cost of identifying a source ously passed stools (SPS).6 To decrease the of occult gastrointestinal bleeding by colo- number of false-positive FOBT results, pa- noscopy in these 2 groups of patients. tients are placed on dietary restrictions, and nonsteroidal anti-inflammatory drug RESULTS (NSAID) and aspirin use is discontinued 1 week before testing. Despite these rec- During the 5-year study period, 672 ommendations, clinicians often test stool asymptomatic average-risk patients with samples for occult blood at the time of digi- From the Division of 7 Gastroenterology, New York tal rectal examination (DRE). Although University Medical Center, widely practiced, this screening method has been discouraged because it is thought This article is also available on our Bellevue Hospital, and New Web site: www.ama-assn.org/internal. York Veterans Affairs Medical to increase the number of false-positive Center, New York, NY. FOBT results.8,9 ARCH INTERN MED/ VOL 159, SEP 27, 1999 2022 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 PATIENTS AND METHODS ENDOSCOPY All colonoscopic examinations were performed by gastro- PATIENTS enterology fellows with an experienced faculty member in attendance. Informed consent was obtained from each pa- Consecutive asymptomatic patients older than 50 years at tient before every procedure. All endoscopic abnormali- average risk for colorectal cancer with a positive FOBT ties were noted, and multiple biopsy specimens were ob- result obtained by DRE or SPS sampling who were tained from each one. All polyps were removed whenever referred to the gastroenterology service at Bellevue Hospi- possible. No major complications directly related to en- tal Center, New York, NY, between January 1992 and doscopy were noted. Lesions that were considered a source January 1997 were identified. Patients were excluded of occult gastrointestinal blood loss included: adenoma- from this study if they had any abdominal signs or symp- tous polyps greater than or equal to 1 cm in diameter, car- toms. Average-risk individuals were defined as patients cinoma, active colitis or inflammatory bowel disease, co- who did not have a history of colon polyps or colorectal lonic ulcers greater than or equal to 1 cm in diameter, and cancer, a family history of colorectal cancer, or inflamma- multiple vascular ectasias. Hemorrhoids and diverticula were tory bowel disease. not considered a source of occult gastrointestinal blood loss. DATA COLLECTION COST OF ENDOSCOPY Data on each patient, which were collected by means of a The cost of endoscopy was estimated by adding the phy- review of endoscopy records, patient charts, and pathol- sician fee under Medicaid reimbursement, the facility fee ogy reports, included age, sex, race, location at the time for endoscopy, and the pathology fee for the biopsy speci- of endoscopy (inpatient vs outpatient), presence of mens. Medicaid reimbursement values were used in the cost comorbid illness, history of peptic ulcer disease, history analysis because this payment method is most applicable of upper or lower gastrointestinal hemorrhage, presence to the Bellevue Hospital Center patient population. The to- of anemia, and use of alcohol, aspirin, NSAIDs, antico- tal estimated cost, including the physician fee, facility fee, agulants, or tobacco. Comorbid illness was defined as and pathology fee, was $739.64 for colonoscopy and $999.64 the presence of any of the following: cardiovascular dis- for colonoscopy with biopsy and/or polypectomy. ease (congestive heart failure, recurrent angina, or endo- carditis), pulmonary disease (pneumonia, pulmonary STATISTICAL ANALYSIS embolus, or chronic obstructive pulmonary disease), liver disease (acute hepatitis, chronic hepatitis, or cir- The diagnostic yield of colonoscopy in patients with a posi- rhosis), renal disease (creatinine level .177 µmol/L [.2 tive FOBT result obtained by DRE was compared with that mg/dL]), neurologic disease (meningitis or central ner- in patients who were found to have occult blood in SPS vous system disease with loss of independence), meta- samples. The cost of identifying a source of occult bleeding, static cancer, or the presence of a systemic bacterial or cost per neoplasm, cost per adenoma, cost per adenoma greater fungal infection. Anemia was defined as a hemoglobin than or equal to 1 cm in diameter, and cost per cancer de- level of less than 140 g/L in men or less than 120 g/L in tected by these 2 methods of screening were calculated. Con- women. Fecal occult blood testing was performed by tinuous variables were compared using a t test or a nonpara- testing 2 samples from each of 3 SPS or 1 specimen metric test, as appropriate. Categorical variables were obtained during DRE using commercially available test compared using the Fisher exact test. A 2-tailed P value of kits (Hemoccult II; SmithKline Diagnostics Inc, San Jose, less than .05 was considered statistically significant. All data Calif) without rehydration. The presence of occult blood are expressed as mean ± SD. Statistical analysis was per- was identified when a positive test result was noted on at formed using a commercially available software package (SPSS least 1 slide. version 7.5 for Windows; SPSS Inc, Chicago, Ill). a positive FOBT result were evaluated by colonoscopy. in diameter, and adenocarcinoma were similar in The patient characteristics are shown in Table 1. Pa- both groups of patients. Also, 7 patients had vascular tients referred for a positive FOBT result obtained by SPS ectasias, 3 had ulcerative colitis, and 1 had Crohn dis- sampling were more likely to be outpatients than those ease. Five of the 7 patients with vascular ectasias had who were tested during DRE. The remaining demo- multiple lesions located in the cecum and ascending graphic and clinical characteristics were similar in both colon; the remaining 2 patients had isolated lesions in groups of patients. the sigmoid colon. Of the 3 patients with ulcerative coli- A colonic source of occult gastrointestinal bleed- tis, 1 had pancolitis, 1 had proctosigmoiditis, and 1 had ing was identified in 145 patients (21.6%). The predic- disease limited to the rectum. The patient with Crohn tive value of a positive FOBT result was no different disease had involvement of the ileum and proximal between those who were tested by DRE and those who colon. Lesions that were thought not to be a cause of had occult bleeding detected by SPS sampling (22.0% occult bleeding included hemorrhoids (125 patients vs 21.3%, P = .85). The lesions detected by colonos- [18.6%]), diverticulosis (49 patients [7.3%]), and both copy are shown in Table 2. The number of patients hemorrhoids and diverticulosis (37 patients [5.5%]). with neoplastic lesions (adenoma or adenocarcinoma), The findings of colonoscopic examination were normal adenomas, adenomas greater than or equal to 1 cm in 249 patients (37.1%). ARCH INTERN MED/ VOL 159, SEP 27, 1999 2023 ©1999 American Medical Association. All rights reserved.
Load more

Recommended publications
  • Serous Papillary Adenocarcinoma of Unknown Primary in a Recurrent Paravaginal Cyst
    Hindawi Case Reports in Obstetrics and Gynecology Volume 2019, Article ID 8125129, 4 pages https://doi.org/10.1155/2019/8125129 Case Report Serous Papillary Adenocarcinoma of Unknown Primary in a Recurrent Paravaginal Cyst Khilen Patel , Advaita Punjala-Patel, Angela Stephens, and John Lue Department of Obstetrics and Gynecology, Augusta University, Medical College of Georgia, 1120 15th St., Augusta, GA 30912, USA Correspondence should be addressed to Khilen Patel; khipatel@augusta.edu Received 14 February 2019; Revised 1 May 2019; Accepted 28 May 2019; Published 10 June 2019 Academic Editor: Giampiero Capobianco Copyright © 2019 Khilen Patel et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cystic lesions located in the paravaginal region are rare. When present, paravaginal cysts are typically benign and are incidentally found on routine gynecological exams; however, rarely they can be malignant. Treatment options for paravaginal cancers are not well studied and early diagnosis may help improve prognosis in these patients. Our case describes a 55-year-old female with a recurrent paravaginal cyst that was remarkable for serous papillary adenocarcinoma despite biopsy and fuid cytology negative for malignancy. Tis case demonstrates that malignancy should be considered highly with a recurrent paravaginal cyst, especially when present over a short interval. 1. Introduction due to postmenopausal symptoms and denied any vaginal bleeding or vaginal discharge. On bimanual examination, the Large paravaginal cysts are rare and when present are most uterus and cervix were noted to be surgically absent; however, commonlybenign.Tesecystscanbeeithercongenitalor alargepelvicmasswaspalpated.Tismasswassmooth, acquired.
    [Show full text]
  • Board Review from ACP MEDICINE
    BOARD REVIEW FROM MEDSCAPE Case-Based InternalInternal Medicine Self-Assessment Questions CLINICAL ESSENTIALS CARDIOVASCULAR MEDICINE DERMATOLOGY ENDOCRINOLOGY GASTROENTEROLOGY HEMATOLOGY IMMUNOLOGY/ALLERGY INFECTIOUS DISEASE INTERDISCIPLINARY MEDICINE METABOLISM NEPHROLOGY NEUROLOGY ONCOLOGY PSYCHIATRY RESPIRATORY MEDICINE RHEUMATOLOGY www.acpmedicine.com BOARD REVIEW FROM MEDSCAPE Case-Based Internal Medicine Self-Assessment Questions Director of Publishing Cynthia M. Chevins Director, Electronic Publishing Liz Pope Managing Editor Erin Michael Kelly Development Editors Nancy Terry, John Heinegg Senior Copy Editor John J. Anello Copy Editor David Terry Art and Design Editor Elizabeth Klarfeld Electronic Composition Diane Joiner, Jennifer Smith Manufacturing Producer Derek Nash © 2005 WebMD Inc. All rights reserved. No part of this book may be reproduced in any form by any means, including photocopying, or translated, trans- mitted, framed, or stored in a retrieval system other than for personal use without the written permission of the publisher. Printed in the United States of America ISBN: 0-9748327-7-4 Published by WebMD Inc. Board Review from Medscape WebMD Professional Publishing 111 Eighth Avenue Suite 700, 7th Floor New York, NY 10011 1-800-545-0554 1-203-790-2087 1-203-790-2066 acpmedicine@webmd.net The authors, editors, and publisher have conscientiously and carefully tried to ensure that recommended measures and drug dosages in these pages are accurate and conform to the standards that prevailed at the time of publication. The reader is advised, however, to check the product information sheet accompanying each drug to be familiar with any changes in the dosage schedule or in the contra- indications. This advice should be taken with particular seriousness if the agent to be administered is a new one or one that is infre- quently used.
    [Show full text]
  • Management of Locally Advanced Rectal Adenocarcinoma Oncology Board Review Manual
    ONCOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE Management of Locally The Hospital Physician Oncology Board Review Advanced Rectal Manual is a study guide for fellows and practicing physicians preparing for board examinations in oncology. Each manual reviews a topic essential Adenocarcinoma to the current practice of oncology. PUBLISHING STAFF Contributors: Nishi Kothari, MD PRESIDENT, GROUP PUBLISHER Assistant Member, Department of Gastrointestinal Bruce M. White Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL SENIOR EDITOR Khaldoun Almhanna, MD, MPH Robert Litchkofski Associate Member, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research EXECUTIVE VICE PRESIDENT Institute, Tampa, FL Barbara T. White EXECUTIVE DIRECTOR OF OPERATIONS Jean M. Gaul Table of Contents Introduction .............................1 Clinical Evaluation and Staging ..............2 Management .............................4 NOTE FROM THE PUBLISHER: This publication has been developed with­ Surveillance and Long-Term Effects ..........8 out involvement of or review by the Amer­ ican Board of Internal Medicine. Conclusion ..............................9 Board Review Questions ...................10 References .............................10 Hospital Physician Board Review Manual www.turner-white.com Management of Locally Advanced Rectal Adenocarcinoma ONCOLOGY BOARD REVIEW MANUAL Management of Locally Advanced Rectal Adenocarcinoma Nishi Kothari, MD, and Khaldoun Almhanna, MD, MPH INTRODUCTION ence to
    [Show full text]
  • Grading Evidence
    Grading Evidence Analysis of the colonoscopic findings in patients with rectal bleeding according to the pattern of their presenting symptoms Journal Diseases of the Colon & Rectum Publisher Springer New York ISSN 0012-3706 (Print) 1530-0358 (Online) Issue Volume 34, Number 5 / May, 1991 Abstract Patients presenting with rectal bleeding were prospectively categorized according to the pattern of their presentation into those with outlet bleeding (n=115), suspicious bleeding (n=59), hemorrhage (n=27), and occult bleeding (n=68). All patients underwent colonoscopy and this was complete in 94 percent. There were 34 patients with carcinoma and 69 with adenomas >1 cm diameter. The percentage of neoplasms proximal to the splenic flexure was 1 percent in outlet bleeding, 24 percent with suspicious bleeding, 75 percent with hemorrhage, and 73 percent with occult bleeding. Barium enema was available in 78 patients and was falsely positive for neoplasms in 21 percent and falsely negative in 45 percent. Colonoscopy is the investigation of choice in patients with suspicious, occult, or severe rectal bleeding. Bleeding of a typical outlet pattern may be investigated by flexible sigmoidoscopy. J Surg Res. 1993 Feb;54(2):136-9. Colonoscopy for intermittent rectal bleeding: impact on patient management. Graham DJ, Pritchard TJ, Bloom AD. Department of Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106. Abstract Rectal bleeding is a frequent presenting symptom of a number of benign anorectal disorders. However, it may also be a warning sign of more significant gastrointestinal pathology. For this reason, full colonic evaluation has been recommended in patients with intermittent bright red rectal bleeding.
    [Show full text]
  • CASE FILES® Family Medicine
    SECOND EDITION CASE FILES® Family Medicine Eugene C. Toy, MD The John S. Dunn, Senior Academic Chair and Program Director The Methodist Hospital Obstetrics and Gynecology Residency Program Houston, Texas Vice Chair of Academic Affairs Department of Obstetrics and Gynecology The Methodist Hospital–Houston Associate Clinical Professor and Clerkship Director Department of Obstetrics and Gynecology University of Texas Medical School at Houston Houston, Texas Donald Briscoe, MD Director, Family Medicine Residency Program and Chair, Department of Family Medicine The Methodist Hospital—Houston Medical Director Houston Community Health Centers, Inc. Houston, Texas Bruce Britton, MD Clinical Associate Professor and Family Medicine Clerkship Director Department of Family and Community Medicine Eastern Virginia Medical School Portsmouth, Virginia Bal Reddy, MD Director of Predoctoral Education Assistant Professor Department of Family Medicine University of Texas Medical School at Houston Houston, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2010 by The McGraw-Hill Companies, Inc. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher. ISBN: 978-0-07-160024-8 MHID: 0-07-160024-8 The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-160023-1, MHID: 0-07-160023-X. All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occur- rence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark.
    [Show full text]
  • Case 18-2004: a 61-Year-Old Man with Rectal Bleeding and a 2-Cm Mass in the Rectum
    The new england journal of medicine case records of the massachusetts general hospital Founded by Richard C. Cabot Nancy Lee Harris, m.d., Editor Jo-Anne O. Shepard, m.d., Associate Editor Stacey M. Ellender, Assistant Editor Sally H. Ebeling, Assistant Editor Christine C. Peters, Assistant Editor Case 18-2004: A 61-Year-Old Man with Rectal Bleeding and a 2-cm Mass in the Rectum Paul C. Shellito, M.D., Jeffrey W. Clark, M.D., Christopher G. Willett, M.D., and Aaron P. Caplan, M.D. presentation of case From the Department of Surgery (P.C.S.), A 61-year-old man was referred to this hospital for treatment of a low rectal adenocar- the Hematology–Oncology Unit, Depart- cinoma. He had been well until five months previously, when he occasionally began to ment of Medicine (J.W.C.), the Department of Radiation Oncology (C.G.W.), and the note blood in his stool. A stool guaiac test was positive. Three weeks before the patient’s Department of Pathology (A.P.C.), Massa- referral, a colonoscopy was performed at another hospital. A sessile polyp, 10 mm in chusetts General Hospital; and the De- diameter, was removed from the right side of the colon and was determined to be a tu- partments of Surgery (P.C.S.), Medicine (J.W.C.), Radiation Oncology (C.G.W.), bular adenoma; a sessile polyp, 4 mm in diameter, was found 80 cm into the left side of and Pathology (A.P.C.), Harvard Medical the colon; it was excised and found to be associated with a hyperplastic polyp containing School.
    [Show full text]
  • Colorectal Cancer Screening Facts
    How Screening Saves Lives Screening Tests for Colorectal Cancer Colorectal cancer almost always develops from precancerous polyps (abnormal growths) in the Below is a list of several tests that are available to screen for colon or rectum. Screening tests can find colorectal cancer. Some are used alone, while others are used in combination with each other. Talk with your doctor about polyps, so they can be removed before they which screening test is best for you. turn into cancer. Screening tests can also find colorectal cancer early, when treatment Fecal Occult Blood Test (FOBT, Hemoccult, works best. Stool Guaiac) This test checks for occult (hidden) blood in the stool. You receive a test kit from your doctor. You may be asked to follow When Should I Begin Screening? a special diet before and during the test. At home, you place a Colorectal Cancer Screening Facts small amount of your stool from three bowel movements in a You should begin screening for colorectal cancer when you row on test cards. You return the cards to your doctor's office turn 50, then continue at regular intervals. However, you may or lab, where the stool samples are checked for hidden blood. need to be tested earlier or more often than other people if: ! You or a close relative have had colorectal polyps or Flexible Sigmoidoscopy colorectal cancer, or This test allows the doctor to examine the lining of your ! You have inflammatory bowel disease. rectum and lower part of your colon using a thin, flexible, lighted tube called a sigmoidoscope. The tube is inserted into What is Colorectal Talk with your doctor about when you should begin screening your rectum and lower part of the colon.
    [Show full text]
  • Mario's ITE Database V2010.007 Document Copy for the Sole
    Mario’s ITE database V2010.007 Document copy for the sole personal use of Dr. Mario Alberto Jimenez Mario’s Family Medicine In-Training Examination (ITE) Database One of the most important objectives in creating this database is to help the physician in organizing and associating topics to increase memorization efficiency and retention. Another important objective is to allow the physician to focus on any particular organ systems or clinical category he/she might be interested by using simple search queries. For instance, in order to search for the organ system category of Cardiovascular, you only need to press Shift+Ctrl+F, type the letters “Car” after a “+” sign in the search box, i.e. type: “+Car” (do not include “ ), and click the search button, or to search for the clinical category of Care of Children, you only need to type: “+Cca” in the search box and click the search button. The ITE database was exported to adobe acrobat format to ease portability, readability and searchability. Other search examples include: questions that more than 50% of residents missed, type “>L”. This database is based on memorization techniques described here: http://www.web-us.com/memory/improving_memory.htm, but if you have difficulty memorizing all that is written here, remember the warning from one of the smartest and most creative minds of our times, Albert Einstein: "the spirit of learning and creative thought are lost in strict rote learning." Organ Systems: Respiratory=Res; Cardiovascular=Car; Musculoskeletal=Mus; Gastrointestinal=Gas; Special Sensory=Sen; Endocrine=End; Integumentary=Int; Neurologic=Neu; Psychogenic=Psy; Reproductive: Female=Ref; Reproductive: Male=Rem; Nephrologic=Nep; Hematologic/Immune=Hem; Nonspecific=Non; Population-based Care=Pbc (Recommendations); Patient-based Systems=Pbs; Clinical Category: Adult Medicine=Adm; Care of the Surgical Patient=Csp; Maternity Care=Mac; Community Medicine=Com; Care of Children and Adolescents=Cca; Mental Health=Mhe; Care of the Elderly=Cel; Care of the Female Patient=Cfp; Emergent & Urgent Care=Euc.
    [Show full text]
  • Avoiding and Identifying Errors in Health Technology Assessment Models
    HealthConclusion Technology Assessment 2010; Vol. 14: No.251 Health Technology Assessment 2010; Vol. 14: No. 25 ChapterAbstract 6 ReferencesStrategies for avoiding errors ListOverview of abbreviations MutualAppendix understanding 1 ExecutiveModelAvoiding complexity summary and identifying errors in health technology assessment models HousekeepingBackground GuidelinesAppendixAim and objectives 2 SkillsMethodsSearch and training strategies ExplanatoryResults analysis concerning methods for preventing errors PlacingAppendixRecommendations the 3findings of the interviews in the context of the literature on avoiding errors ResearchCharts recommendations Avoiding and identifying errors in Chapter 7 ChapterHealthStrategies Technology 1 for identifying Assessment errors reports published to date health technology assessment models: OverviewIntroduction CheckHealthBackground face Technology validity with Assessment experts programme qualitative study and methodological DoAim the and results objectives appear reasonable? Testing model behaviour review ChapterIs the model 2 able to reproduce its inputs? CanMethods the model replicate other data not used in its construction? J Chilcott, P Tappenden, A Rawdin, CompareMethods answersoverview with the answers generated by alternative models PeerIn-depth review interviews of models with HTA modellers M Johnson, E Kaltenthaler, S Paisley, DoubleLiterature checking review of search input valuesmethods Double-programmingValidity checking D Papaioannou and A Shippam ExplanatoryThe organisation analysis of
    [Show full text]
  • Centre for Reviews and Dissemination Diagnostic Accuracy and Cost
    Centre for Reviews and Dissemination Diagnostic Accuracy and Cost-Effectiveness of Faecal Occult Blood Tests Diagnostic Accuracy and Cost-Effectiveness of Faecal Occult Blood Tests Used in Screening for Colorectal Cancer: A Systematic Review 36 Promoting the use of research based knowledge REPORT 36 CRD DIAGNOSTIC ACCURACY AND COST-EFFECTIVENESS OF FAECAL OCCULT BLOOD TESTS (FOBT) USED IN SCREENING FOR COLORECTAL CANCER: A SYSTEMATIC REVIEW Karla Soares-Weiser1 Jane Burch 1 Steven Duffy1 James St John2 Stephen Smith Marie Westwood1 Jos Kleijnen1 1 Centre for Reviews and Dissemination, University of York, York 2 The Cancer Council Victoria, Melbourne, Australia 3 University Hospitals of Coventry & Warwickshire, Coventry February 2007 © 2007 Centre for Reviews and Dissemination, University of York ISBN 978-1-900640-44-2 This report can be ordered from: Publications Office, Centre for Reviews and Dissemination, University of York, York YO10 5DD. Telephone 01904 321458; Facsimile: 01904 321035: email: crd-pub@york.ac.uk Price £12.50 The Centre for Reviews and Dissemination is funded by the NHS Executive and the Health Departments of Wales and Northern Ireland. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or the Health Departments of Wales or Northern Ireland. Printed by York Publishing Services Ltd. ii CENTRE FOR REVIEWS AND DISSEMINATION The Centre for Reviews and Dissemination (CRD) is a facility commissioned by the NHS Research and Development Division. Its aim is to identify and review the results of good quality health research and to disseminate actively the findings to key decision makers in the NHS and to consumers of health care services.
    [Show full text]
  • The Hemo-Quik
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Supervised Undergraduate Student Research Chancellor’s Honors Program Projects and Creative Work 5-2014 The Hemo-Quik Michelle Morin University of Tennessee - Knoxville, mmorin@utk.edu Follow this and additional works at: https://trace.tennessee.edu/utk_chanhonoproj Part of the Biomedical Devices and Instrumentation Commons, and the Systems and Integrative Engineering Commons Recommended Citation Morin, Michelle, "The Hemo-Quik" (2014). Chancellor’s Honors Program Projects. https://trace.tennessee.edu/utk_chanhonoproj/1783 This Dissertation/Thesis is brought to you for free and open access by the Supervised Undergraduate Student Research and Creative Work at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Chancellor’s Honors Program Projects by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu. The Hemo-Quik - Designed for Project Stakeholder - Dr. Matthew Mihelic, M.D. Associate Professor – Department of Family Medicine University of Tennessee Graduate School of Medicine April 24, 2014 Presented by Stool Solutions Design Team Michelle Morin (443) 968-1458 // mmorin@utk.edu Bill McClintic (423) 845-0198 // wmcclint@utk.edu Patrick Jones (865) 202-9803 // pjones34@utk.edu Derek Shambo (865) 771-0347 // dshambo@utk.edu Table of Contents Executive Summary……………………………………………….…………………………….1 Background…………………………………………………………….………………………1-3 Problem Definition…………………………………………………….………………...........3-4 Conceptual Development…………………………………………………………………….4-9 Product Description…………………………………………………...……….…………….9-16 Design Evaluation……………………………………………………………………....…..16-19 Recommendations and Future Work……………………………………………..………19-20 Appendix: Sensitivity Testing Results……………………………………….……………21-23 References………………………………………………………………………………………24 Executive Summary This report serves to introduce the Hemo-Quik, a streamlined device for quick, easy, and reliable fecal occult blood detection.
    [Show full text]
  • Three in 10 Diabetic Patients May Have Liver Fibrosis Many Drugs in The
    VOL. 12 NO. 3 MARCH 2018 ® Many drugs in the INSIDE IBD AND INTESTINAL pipeline for IBD DISORDERS High BMI linked to problems in IBD treatment Obesity related to EWS N increased rate of BY DOUG BRUNK sentation by highlighting ICAL hospitalization. • 23 ED Frontline Medical News anti-integrin therapies M for inflammatory bowel LIVER DISEASE LAS VEGAS – A wide disease (IBD) treatment. Obesity affects the RONTLINE /F variety of drugs are in These leukocyte membrane ability to diagnose the pipeline for both ul- glycoproteins target beta1 RUNK B cerative colitis (UC) and and beta7 subunits. They liver fibrosis OUG As BMI increases, so does D Crohn’s disease patients interact with endothelial li- Dr. Kenneth Cusi said, “Patients with diabetes [type 2] face the who are failing currently gands VCAM-1, fibronectin, discordance between greatest risk of fatty liver and of fibrosis.” available therapies. and MadCAM-1, and medi- imaging techniques. • 32 “The challenge for all ate leukocyte adhesion and GI ONCOLOGY of us is to integrate the trafficking. Approved an- Circulating tumor cell Three in 10 diabetic right drugs for the right ti-integrin therapies to date patients,” William J. Sand- include natalizumab and assay for CRC born, MD, AGAF, said at vedolizumab, while inves- High sensitivity and patients may have the annual congress of the tigational therapies include specificity reported. • 38 Crohn’s & Colitis Founda- etrolizumab, PF-00547659, tion, a partnership of the abrilumab, and AJM 300. AGA GUIDELINE liver fibrosis Crohn’s & Colitis Foun- In a phase 2 study of Use goal-directed dation and the American etrolizumab as induction fluid therapy, early BY DOUG BRUNK to treat it,” he said at the Gastroenterological Asso- therapy for moderate to se- refeeding in acute Frontline Medical News World Congress on Insulin ciation.
    [Show full text]